Opinion
Volume 13:01, 2024

International Journal of Drug Research and Technology

ISSN: 2277-1506 Open Access

Chasing Solutions for COVID-19: An Overview of Antiviral Therapies

Siripat Chaichit*

Department of Pharmaceutical Biosciences, University of Helsinki, 00014 University of Helsinki, Finland

Introduction

An expedited approach to drug development involves repurposing existing medications. Researchers have evaluated various drugs originally intended for different viral infections, including remdesivir (initially designed for Ebola) and the antimalarial drug hydroxychloroquine. While some initially displayed promise, subsequent research has provided clarity on their effectiveness. Monoclonal antibodies, synthetic proteins emulating the immune system's pathogen-fighting capabilities, have emerged as a significant avenue. Treatments like REGN-COV2 and bamlanivimab/etesevimab have received emergency use authorization for treating COVID-19 patients. Additionally, certain drugs like lopinavir and ritonavir, designed to inhibit viral proteases crucial for replication, have not shown clear benefits in clinical trials, resulting in limited use. Exploration of RNA-based therapies, such as small interfering RNA and Antisense Oligonucleotides (ASOs), has been underway to target and inhibit the virus's genetic material. Promising results from preclinical studies highlight the potential of these therapies in the pursuit of effective treatments for COVID-19 [1].

Description

SARS-CoV-2, a novel coronavirus, caused a global pandemic at the end of 2019 and prompted an immediate demand for effective treatments. As the world wrestled with the staggering effects of Coronavirus, researchers and analysts across the globe prepared to create and reuse medications to battle the infection. This article investigates the continuous journey for Covid drugs, revealing insight into the techniques, challenges and promising applicants in the fight against this worldwide danger. Variants of coronaviruses are created when they undergo mutation. Drug improvement should represent these transformations to stay compelling. Thorough clinical preliminaries are important to guarantee a medication's wellbeing and viability. These preliminaries take time and not all medications that show guarantee in the lab perform well in human examinations. It can be difficult logistically to increase production and ensure equitable distribution of effective drugs, particularly in developing nations. Coronavirus influences patients in an unexpected way and a one-size-fits-all medication may not be doable. Fitting medicines to individual patient profiles is a developing area of examination [2,3].

This antiviral prescription was one of the principal drugs approved for crisis use to treat Coronavirus. It works by disrupting the infection's capacity to imitate. Clinical preliminaries have given blended results with respect to its adequacy. This is a corticosteroid used to diminish irritation and has been viewed as powerful in decreasing mortality in serious instances of Coronavirus. Frequently utilized in hospitalized patients require supplemental oxygen or mechanical ventilation. Monoclonal immune response treatments, for example, casirivimab/imdevimab and bamlanivimab/etesevimab, have been approved for crisis use. They are utilized to treat gentle to direct instances of Coronavirus and are best when managed right off the bat throughout the sickness. Healing plasma treatment includes utilizing the plasma from recuperated Coronavirus patients, which contains antibodies against the infection, to treat tainted people. Its viability is as yet a subject of exploration. Ivermectin is an antiparasitic drug that acquired consideration as a potential Coronavirus treatment. Notwithstanding, its viability and security for Coronavirus were under discussion and more exploration was required [4].

onvalescent plasma therapy involves collecting plasma from individuals who have recovered from COVID-19 and transfusing it into patients currently fighting the infection. The idea is that the antibodies present in the plasma may help the recipient's immune system combat the virus. While this therapy was widely used early in the pandemic, its efficacy has been questioned and more rigorous studies are needed to determine its effectiveness. Monoclonal antibodies are laboratory-made proteins that mimic the immune system's ability to fight off harmful pathogens such as viruses. Several monoclonal antibody treatments have received emergency use authorization for COVID-19, including casirivimab/imdevimab (REGN-COV2) and bamlanivimab/etesevimab. These treatments have been shown to reduce the risk of severe disease and hospitalization in high-risk patients when administered early in the course of illness. Developed by Merck and Ridgeback Biotherapeutics, this oral antiviral drug aims to impede the replication of the SARS-CoV-2 virus. It demonstrated significant efficacy in clinical trials, notably reducing the risk of hospitalization or death. A promising combination of nirmatrelvir and ritonavir, inhibiting viral proteases, along with molnupiravir, has shown potential as a COVID-19 treatment. Convalescent plasma, containing antibodies from recovered COVID-19 patients, remains a crucial therapeutic option, particularly for severe cases [5].

Conclusion

The quest for effective coronavirus drugs persists, with researchers tirelessly working to discover treatments that can alleviate the impact of the ongoing pandemic. Despite challenges, ongoing drug development and repurposing efforts, coupled with advancements in understanding the virus and its variants, instill hope for more effective treatments. As science and medicine evolve, the battle against COVID-19 remains a top priority, underscoring the vital role of global collaboration and innovation in the ongoing fight against infectious diseases.

References

1. Richley, Michael, Rashmi R. Rao, Yalda Afshar and Jenny Mei, et al. "Neutralizing monoclonal antibodies for coronavirus disease 2019 (COVID-19) in pregnancy: A case series." *Obstet Gynecol* 139 (2022): 368.

2. Levey, Natalie H., Alexandra D. Forrest, Daniella W. Spielman and Kirk A. Easley, et al. "Outcomes of pregnant patients treated with REGEN-COV during the COVID-19 pandemic." *Am J Obstet Gynecol MFM* 4 (2022): 100673.

3. Tuan, Jessica J., Manas Sharma, Jehanzeb Kayani and Matthew W. Davis, et

***Address for Correspondence:** Siripat Chaichit, Department of Pharmaceutical Biosciences, University of Helsinki, 00014 University of Helsinki, Finland, E-mail: siripat11@gmail.com*

Received: 02 January, 2024, Manuscript No. IJDRT-24-127105; **Editor assigned:** 04 January, 2024, PreQC No. P-127105; **Reviewed:** 15 January, 2024, QC No. Q-127105; **Revised:** 22 January, 2024, Manuscript No. R-127105; **Published**: 29 January, 2024, DOI: 10.37421/2277-1506.2024.13.437

al. "Outcomes of pregnant women exposed to Sotrovimab for the treatment of COVID-19 in the BA. 1 Omicron predominant era (PRESTO)." *BMC Infect Dis* 23 (2023): 258.

4. Metz, Torri D., Rebecca G. Clifton, Brenna L. Hughes and Grecio J. Sandoval, et al. "Association of SARS-CoV-2 infection with serious maternal morbidity and mortality from obstetric complications." *Jama* 327 (2022): 748-759.

5. DeSisto, Carla L., Bailey Wallace, Regina M. Simeone and Kara Polen, et al. "Risk for stillbirth among women with and without COVID-19 at delivery hospitalization—United States, March 2020–September 2021." *Morb Mortal Wkly Rep* 70 (2021): 1640.

How to cite this article: Chaichit, Siripat. "Chasing Solutions for COVID-19: An Overview of Antiviral Therapies." *Int J Drug Res Tech* 13 (2024): 437.